HRP20201250T1 - Topikalni pripravci koji sadrže kortikosteroid i retinoid namijenjeni liječenju psorijaze - Google Patents

Topikalni pripravci koji sadrže kortikosteroid i retinoid namijenjeni liječenju psorijaze Download PDF

Info

Publication number
HRP20201250T1
HRP20201250T1 HRP20201250TT HRP20201250T HRP20201250T1 HR P20201250 T1 HRP20201250 T1 HR P20201250T1 HR P20201250T T HRP20201250T T HR P20201250TT HR P20201250 T HRP20201250 T HR P20201250T HR P20201250 T1 HRP20201250 T1 HR P20201250T1
Authority
HR
Croatia
Prior art keywords
accordance
topical pharmaceutical
pharmaceutical preparation
intended
preparation intended
Prior art date
Application number
HRP20201250TT
Other languages
English (en)
Croatian (hr)
Inventor
Gordon J. Dow
Radhakrishnan Pillai
Varsha BHATT
Original Assignee
Bausch Health Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56131662&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20201250(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bausch Health Ireland Limited filed Critical Bausch Health Ireland Limited
Publication of HRP20201250T1 publication Critical patent/HRP20201250T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/12Aerosols; Foams
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
HRP20201250TT 2015-06-18 2016-06-06 Topikalni pripravci koji sadrže kortikosteroid i retinoid namijenjeni liječenju psorijaze HRP20201250T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562181481P 2015-06-18 2015-06-18
EP16729470.1A EP3310389B1 (en) 2015-06-18 2016-06-06 Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis
PCT/US2016/035991 WO2016205001A1 (en) 2015-06-18 2016-06-06 Topical compositions comprising a corticosteroid and a retinoid for treating psoriasis

Publications (1)

Publication Number Publication Date
HRP20201250T1 true HRP20201250T1 (hr) 2020-11-13

Family

ID=56131662

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201250TT HRP20201250T1 (hr) 2015-06-18 2016-06-06 Topikalni pripravci koji sadrže kortikosteroid i retinoid namijenjeni liječenju psorijaze

Country Status (20)

Country Link
US (7) US10251895B2 (enExample)
EP (1) EP3310389B1 (enExample)
JP (1) JP6997624B2 (enExample)
KR (2) KR102643849B1 (enExample)
CN (1) CN108282998B (enExample)
AU (1) AU2016279801B2 (enExample)
BR (1) BR112017027332B1 (enExample)
CA (1) CA2988577A1 (enExample)
CY (1) CY1123354T1 (enExample)
DK (1) DK3310389T3 (enExample)
ES (1) ES2812451T3 (enExample)
HR (1) HRP20201250T1 (enExample)
HU (1) HUE050603T2 (enExample)
LT (1) LT3310389T (enExample)
MX (1) MX377544B (enExample)
PL (1) PL3310389T3 (enExample)
PT (1) PT3310389T (enExample)
RS (1) RS60672B1 (enExample)
SI (1) SI3310389T1 (enExample)
WO (1) WO2016205001A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
CN108282998B (zh) 2015-06-18 2021-07-06 凡利亚药品北美公司 用于治疗银屑病的包含皮质类固醇和类视黄醇的局部组合物
AU2016294504B2 (en) * 2015-07-13 2019-07-18 Dr. Reddy's Laboratories, Ltd. Topical retinoid compositions
CA3063371A1 (en) * 2017-05-12 2018-11-15 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
US11311482B2 (en) * 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
US10857160B2 (en) * 2017-06-23 2020-12-08 Laboratorios Salvat, S.A. Oil-in-water nanoemulsion composition of clobetasol
CA3095907A1 (en) * 2018-04-05 2019-10-10 Bausch Health Ireland Limited Polymeric emulsion delivery systems
US10653656B2 (en) 2018-04-05 2020-05-19 Bausch Health Ireland Limited Topical pharmaceutical compositions for treating skin conditions
CA3133174A1 (en) 2019-03-14 2020-09-17 Crescita Therapeutics Inc. Rinse-off compositions and uses thereof for delivery of active agents
KR102327827B1 (ko) 2019-11-01 2021-11-18 한국과학기술연구원 강황 추출물을 유효성분으로 포함하고 자외선 처리를 포함하는 건선 개선용 조성물
CN113116891B (zh) * 2019-12-30 2024-07-16 重庆华邦制药有限公司 一种乳膏及其制备方法
KR102451304B1 (ko) 2020-09-14 2022-10-07 한국과학기술연구원 꿩의다리속 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR102527907B1 (ko) 2020-09-14 2023-05-03 한국과학기술연구원 무산상자 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR102461001B1 (ko) 2020-09-14 2022-11-01 한국과학기술연구원 술패랭이꽃 추출물을 유효성분으로 포함하는 건선 개선용 조성물
KR102692893B1 (ko) 2021-09-17 2024-08-08 한국과학기술연구원 시미시푸고라이드 에이를 유효성분으로 포함하는 건선 개선용 조성물
KR102769642B1 (ko) 2021-09-17 2025-02-20 한국과학기술연구원 눈개승마 추출물을 유효성분으로 포함하는 건선 개선용 조성물
CN113975249B (zh) * 2021-10-14 2023-01-03 中山大学·深圳 Tris-BNP纳米颗粒的制备及其在皮肤疾病治疗中的应用
CN113712918A (zh) * 2021-10-28 2021-11-30 济南纽华医药科技有限公司 一种阿普斯特微乳及其制备方法
WO2024141639A1 (en) * 2022-12-31 2024-07-04 Bausch Health Ireland Limited Use of a fixed combination of halobetasol propionate and tazarotene to treat conditions mediated by interleukin-17a
WO2024201481A1 (en) * 2023-03-29 2024-10-03 Scires Technologies Private Limited Anti-psoriasis topical formulation containing combination drugs and method of preparation thereof

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU75903A1 (enExample) 1976-09-29 1978-05-16
NL7105591A (en) 1971-04-24 1972-10-26 Topical antiphlogistic compsns - contng 3, 20-diketo-9 alpha, 11 beta-dichloro - 16 alpha, 17 alpha-dimethyl-21-hydroxy pregna-1,4-
DE2655570A1 (de) 1975-12-12 1977-06-16 Ciba Geigy Ag Neue polyhalogensteroide und verfahren zu ihrer herstellung
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
US4083974A (en) 1977-03-07 1978-04-11 The Upjohn Company Topical steroidal anti-inflammatory preparations containing polyoxypropylene 15 stearyl ether
JPS5850964B2 (ja) 1978-03-07 1983-11-14 東興薬品工業株式会社 ステロイド含有クリ−ム製剤およびその製造方法
US4299828A (en) 1979-05-31 1981-11-10 E. R. Squibb & Sons, Inc. Corticosteroid stick formulations
AU5794680A (en) 1979-05-31 1980-12-04 E.R. Squibb & Sons, Inc. Corticosteroid stick formulations
US4233295A (en) 1979-05-31 1980-11-11 E. R. Squibb & Sons, Inc. Corticosteroid formulations containing sebacate carrier
PT73772B (en) 1980-10-06 1983-10-14 Glaxo Group Ltd Topically administrable pharmaceutical compositions containing anti-inflammatory steroids
JPS58225009A (ja) 1982-06-23 1983-12-27 Shionogi & Co Ltd コルチコステロイド外用製剤
DE3225848A1 (de) 1982-07-07 1984-01-19 Schering AG, 1000 Berlin und 4709 Bergkamen Kortikoidhaltige zubereitung zur topischen applikation
GB8401965D0 (en) 1984-01-25 1984-02-29 Beecham Group Plc Composition
CA1303991C (en) 1986-03-31 1992-06-23 Chung H. Cheng Composition and method for delivering a steroid active ingredient
US5019569A (en) 1986-11-03 1991-05-28 Ortho Pharmaceutical Corporation Reversal of glucocorticoid-induced skin atrophy
JPH0676328B2 (ja) 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイドクリ−ム製剤
JPH0676327B2 (ja) 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイド軟膏製剤
JPH07116026B2 (ja) 1987-07-07 1995-12-13 株式会社資生堂 ジクロフェナックナトリウム含有乳化外用剤
US5422361A (en) 1989-12-20 1995-06-06 Schering Corporation Stable cream and lotion bases for lipophilic drug compositions
DE69116257T2 (de) 1990-03-02 1996-06-27 Shiseido Co Ltd Wässerige emulsion mit nicht steroidhaltigen entzündungshemmenden schmerzmitteln
TW218849B (enExample) * 1991-05-17 1994-01-11 Bristol Myers Squibb Co
US5326566A (en) 1991-05-17 1994-07-05 Bristol-Myers Squibb Company Use of dibutyl adipate and isopropyl myristate in topical and transdermal products
WO1998036753A1 (en) 1997-02-20 1998-08-27 Allergan Sales,Inc. Tazarotene and corticosteroid treatment for psoriasis
SE9800729L (sv) 1998-03-06 1999-09-07 Scotia Lipidteknik Ab Ny topikal formulering I
GB9823036D0 (en) 1998-10-22 1998-12-16 Glaxo Group Ltd Fluticasone lotion having improved vasoconstrictor activity
AU2877800A (en) * 1999-02-12 2000-08-29 Susan Bershad Short contact treatment of psoriasis with topical retinoids
US6730308B1 (en) * 1999-03-08 2004-05-04 Allergan, Inc. Tazarotene and alpha hydroxy acid treatment for psoriasis and/or photodamage
US6479058B1 (en) 1999-09-02 2002-11-12 Mccadden Michael E. Composition for the topical treatment of poison ivy and other forms of contact dermatitis
US6656928B1 (en) 1999-09-02 2003-12-02 Mccadden Michael E. Composition for the topical treatment of rashes, dermatoses and lesions
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
JP4451061B2 (ja) * 2000-10-27 2010-04-14 レオ ファーマ アクティーゼルスカブ 少なくとも1つのビタミンdまたは1つのビタミンdアナログおよび少なくとも1つのコルチコステロイドを含有する局所用組成物
US6709663B2 (en) 2001-08-31 2004-03-23 Healthpoint, Ltd. Multivesicular emulsion drug delivery systems
US6765001B2 (en) 2001-12-21 2004-07-20 Medicis Pharmaceutical Corporation Compositions and methods for enhancing corticosteroid delivery
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US7820145B2 (en) 2003-08-04 2010-10-26 Foamix Ltd. Oleaginous pharmaceutical and cosmetic foam
US7544674B2 (en) 2002-10-25 2009-06-09 Galderma S.A. Topical skin care composition
CN1210034C (zh) * 2002-12-06 2005-07-13 重庆华邦制药股份有限公司 治疗银屑病的药物组合物
WO2004058262A1 (en) 2002-12-31 2004-07-15 Wockhardt Limited Benzoquinolizine-2-carboxylic acid-containing compositions
JP2004359585A (ja) 2003-06-03 2004-12-24 Medorekkusu:Kk 被膜形成型の副腎皮質ステロイド薬含有外用製剤
CN1210035C (zh) * 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 治疗银屑病的复方外用药物
CN1210041C (zh) * 2003-09-29 2005-07-13 中国医学科学院皮肤病研究所 治疗痤疮的复方外用药物
US8741333B2 (en) 2004-06-07 2014-06-03 Nuvo Research Inc. Compositions and methods for treating dermatitis or psoriasis
WO2006098353A1 (ja) 2005-03-15 2006-09-21 Kyowa Hakko Kogyo Co., Ltd. 外用剤
TW200740441A (en) 2005-06-17 2007-11-01 Combinatorx Inc Methods and reagents for the treatment of inflammatory disorders
AU2006339350A1 (en) 2005-12-14 2007-09-07 Zars Pharma, Inc. Compositions and methods for dermal delivery of drugs
PL2494959T3 (pl) 2006-07-05 2015-06-30 Foamix Pharmaceuticals Ltd Nośnik ze spienialnego kwasu dikarboksylowego oraz kompozycje farmaceutyczne z nośnikiem
AU2007355106A1 (en) 2006-11-29 2008-12-18 Foamix Ltd. Foamable waterless compositions with modulating agents
WO2009063493A2 (en) 2007-09-10 2009-05-22 Glenmark Pharmaceuticals Limited Topical pharmaceutical composition for the combination of fusidic acid and a corticosteroid
WO2009084020A2 (en) 2007-10-18 2009-07-09 Glenmark Pharmaceuticals Limited Topical composition comprising halobetasol and salicylic acid
KR20160130519A (ko) 2008-06-26 2016-11-11 안테리오스, 인코퍼레이티드 경피 운반
PT2400951T (pt) 2009-02-25 2018-11-26 Mayne Pharma Llc Composições de espuma tópica
US20130310355A1 (en) 2009-12-15 2013-11-21 Young Pharmaceuticals, Inc. Low toxicity topical active agent delivery system
WO2012051614A2 (en) 2010-10-15 2012-04-19 Kulesza John E Delivery of hydrophobic bioactive agents
CN107308163A (zh) * 2010-11-04 2017-11-03 442合资有限责任公司 用于治疗皮肤病的组合物和方法
US8809307B2 (en) * 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US9034926B2 (en) * 2010-12-30 2015-05-19 Nicholas V. Perricone Topical nitrone spin trap compositions for psoriasis
US20120328670A1 (en) 2011-06-03 2012-12-27 Allergan, Inc. Targeted Delivery of Retinoid Compounds to the Sebaceous Glands
SG11201403762PA (en) 2012-01-09 2014-07-30 Almirall Sa Topical pharmaceutical compositions comprising bexarotene and a corticosteroids
US20140112959A1 (en) 2012-10-18 2014-04-24 MiCal Pharmaceuticals LLC - H Series, a Series of MiCal Pharmaceuticals LLC, a Multi-Division Limite Topical steroid composition and method
CN104288157B (zh) * 2013-01-29 2018-04-13 江苏知原药业有限公司 包含丙酸氯倍他索和维a酸的固体分散体及其制备方法
US20160256474A1 (en) * 2013-09-25 2016-09-08 Sun Pharmaceutical Industries Limited Topical spray composition of halobetasol
US20190133943A1 (en) 2015-06-18 2019-05-09 Valeant Pharmaceuticals North America Topical compositions and methods for treating skin diseases
CN108282998B (zh) 2015-06-18 2021-07-06 凡利亚药品北美公司 用于治疗银屑病的包含皮质类固醇和类视黄醇的局部组合物
US11311482B2 (en) * 2017-05-12 2022-04-26 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases
CA3063371A1 (en) 2017-05-12 2018-11-15 Bausch Health Us, Llc Topical compositions and methods for treating skin diseases

Also Published As

Publication number Publication date
US20230086282A1 (en) 2023-03-23
US11648256B2 (en) 2023-05-16
HUE050603T2 (hu) 2020-12-28
DK3310389T3 (da) 2020-08-10
CN108282998B (zh) 2021-07-06
MX2017015990A (es) 2018-11-09
MX377544B (es) 2025-03-10
KR102643849B1 (ko) 2024-03-07
US20210145847A1 (en) 2021-05-20
KR20240035898A (ko) 2024-03-18
EP3310389B1 (en) 2020-07-01
PT3310389T (pt) 2020-11-11
US10426787B2 (en) 2019-10-01
CA2988577A1 (en) 2016-12-22
LT3310389T (lt) 2020-11-10
CY1123354T1 (el) 2021-12-31
US10251895B2 (en) 2019-04-09
KR20180053292A (ko) 2018-05-21
BR112017027332B1 (pt) 2023-11-07
RS60672B1 (sr) 2020-09-30
US20210330681A1 (en) 2021-10-28
BR112017027332A2 (pt) 2018-09-04
WO2016205001A1 (en) 2016-12-22
US11679115B2 (en) 2023-06-20
ES2812451T3 (es) 2021-03-17
CN108282998A (zh) 2018-07-13
US20190231797A1 (en) 2019-08-01
US11679116B2 (en) 2023-06-20
SI3310389T1 (sl) 2020-11-30
PL3310389T3 (pl) 2020-11-30
EP3310389A1 (en) 2018-04-25
KR102779108B1 (ko) 2025-03-07
AU2016279801B2 (en) 2021-09-09
US20160367570A1 (en) 2016-12-22
JP6997624B2 (ja) 2022-01-17
AU2016279801A1 (en) 2018-01-04
JP2018526325A (ja) 2018-09-13
US20180177803A1 (en) 2018-06-28
US20230355640A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
HRP20201250T1 (hr) Topikalni pripravci koji sadrže kortikosteroid i retinoid namijenjeni liječenju psorijaze
JP2018526325A5 (enExample)
EP3334449A4 (en) METHOD AND PHARMACEUTICAL COMPOSITIONS FOR IMPROVING WOUND HEALING USING CD24
IL250239A0 (en) Method for the preparation of (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1-6-naphthyridine-3-carbox-amide and the purification thereof for use as an active pharmaceutical ingredient
FR3024037B1 (fr) Ingredient actif cosmetique ou dermatologique comprenant un melange d'acides dicarboxyliques gras insatures, compositions le comprenant et utilisations cosmetiques ou dermatologiques
BR112017024940A2 (pt) composições de óleo essencial e seu método
DK3224268T3 (da) Nye 2'- og/eller 5'-aminosyreesterphosphoramidat 3'-deoxyadenosinderivater som anti-cancerforbindelser
CL2016001777A1 (es) Composición herbicida que contiene ácido 4-amino-3-cloro-6-(4-cloro-2-fluoro-3-metoxifenil) piridin-2-carboxílico o sus derivados, fluroxipir o sus derivados y fenoxiauxinas o sus derivados
MX390089B (es) Composiciones de aceite refinado y métodos para su elaboración.
EA201790949A1 (ru) Замещенные 2,4-диаминохинолины в качестве новых противораковых средств
EA201891856A1 (ru) Новые наноэмульсии, содержащие жирную кислоту и соль n-ацильных производных аминокислоты
MX385987B (es) Intensificadores de aceptabilidad para alimento para mascotas, método de preparación y usos de los mismos.
RU2018109969A (ru) Экстракт гардении для окрашивания кожи
MX387472B (es) Composiciones para el cuidado bucal y sistema para dispensar las mismas.
WO2017106367A8 (en) Method of treating neurodegenerative disorders by rescuing alpha-synuclein toxicity
EP3326628A4 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION WITH HIGH-CONCENTRATED TAXAN
CL2014001833A1 (es) Uso de cascaras de palta con el fin de obtener un insaponificable de palta enriquecido en hidrocarburos alifaticos saturados y en esteroles, donde las cascaras representan del 5 al 50% en peso en relacion al peso total de las paltas utilizadas; metodo para obtener un insaponificable de palta; y dicho producto.
BR112018010928A2 (pt) método de tratamento de uma corrente, e, líquido de desempenho multicomponente
EP3360581A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF CANCER WITH INHIBITOR OF PLRG1 (PLEIOTROPER REGULATOR 1) AS AN ACTIVE SUBSTANCE
EA201650066A1 (ru) Липосомы, содержащие дигомо-гамма-линоленовую кислоту (дглк), содержащие их композиции и их применение
EA201790117A1 (ru) Фармацевтическая композиция, содержащая 13 глицеридов, и ее препараты и их применение
AR106592A1 (es) Emulsión de gas en aceite en agua y método para su preparación
TH162758A (th) องค์ประกอบที่ใช้สำหรับช่องปาก
ES2575127B2 (es) Mercaptoftalocianinas, procedimiento de preparación de las mismas y su anclaje a nanopartículas metálicas
TH168845A (th) สารองค์ประกอบไขน้ำมันสำหรับแป้งนวดของจำพวกเส้นบะหมี่และไขน้ำมันสำหรับ แป้งนวดของจำพวกเส้นบะหมี่และวิธีผลิตจำพวกเส้นบะหมี่